share_log

Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Maintains $7 Price Target

Benzinga ·  Jun 27 08:32

Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $7 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment